Equillium (NASDAQ: EQ)
$1.61
(-6.9%)
-$0.12
Price as of April 19, 2024, 4:00 p.m. ET
Equillium Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Equillium Company Info
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March, 2017 and is headquartered in La Jolla, CA.
News & Analysis
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.